Analytics 4 Life said today that it landed $25 million in a Series B financing round. A group of investors, including doctors and medical device experts, contributed to the round.
The digital health company’s cardiac imaging tech is designed to help physicians assess the presence of coronary artery disease using signals from the body – without the use of radiation or contrast agents.
The company’s first application of its technology is CorVista, a non-invasive diagnostic test that uses an array of sensors to scan signals naturally given from the body. When the sensors are finished collecting data, the signal package is transmitted to the cloud. There, it is analyzed by a machine-learning algorithm which generates a unique image and model of the heart, pointing towards areas of potential heart disease.
The results of the test are presented on a physician web portal.
“Heart disease is the leading cause of death globally, with 1 in 7 deaths in the U.S. attributed to CAD. We are thankful for the continued support from passionate investors who have made it possible for us to revolutionize the way that CAD is diagnosed,” CEO Don Crawford said in prepared remarks. “Securing this oversubscribed financing fuels our rapid growth to advance development of our diagnostic tool and gives us the resources we need to deliver this game-changing technology to patients and physicians.”
The CorVista test is being evaluated in an on-going, two-stage clinical trial with more than 2,000 patients, the company reported. The study plans to compare the performance of a machine-learned algorithm for CAD detection with cardiac catheterization results.
The company expects to present preliminary results from the trial next month at the Transcatheter Cardiovascular Therapeutics conference in Denver.
Analytics 4 Life also said today that Dr. Aaron Berez, founder & CEO of Alembic LLC, joined the company’s board of directors.
“Today marks an important milestone for the company, but also for the 15.5 million Americans living with coronary heart disease,” Berez said. “I’m excited and honored to join Analytics 4 Life’s Board of esteemed experts as we chart a path toward bringing this potentially transformative way to diagnose cardiovascular disease to patients and physicians.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.